azd-7624
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01754844)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](NC(=O)c1cc(-c2ccccc2)nc2ccccc12)c1ccccc1- Mol. weight
- 366.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL9960 ↗
Also known as
- azd7624
- azd-7624
- azd-7624
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02753764 | Phase 2 | Jan 1, 2017 | University of Colorado, Denver |
| NCT02238483 | Phase 2 | Oct 1, 2014 | AstraZeneca, University of Colorado, Denver |
| NCT01937338 | Phase 1 | Oct 1, 2013 | AstraZeneca, IQVIA |
| NCT01817855 | Phase 1 | Sep 1, 2013 | AstraZeneca, IQVIA |
| NCT01754844 | Phase 1 | Jan 1, 2013 | AstraZeneca, IQVIA |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 2 | 2013 |
| IQVIA | For profit | 3 | 0 | 1 | 2013 |
| University of Colorado, Denver | Academic/Hospital | 2 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1